Davis Polk advised the underwriter, SVB Securities, in the offering. Applied Therapeutics, Inc. announced its offering of 20,000,000 shares of common stock, pre-funded warrants to purchase up...
Applied Therapeutics’ $30 Million Stock and Warrants Offering
GSK’s $3.3 Billion Acquisition of Affinivax
Davis Polk advised GSK plc on the deal while Gunderson Dettmer represented Affinivax. GSK plc announced its acquisition of Affinivax, Inc. for a $2.1 billion upfront...
PayPal’s $3 Billion Notes Offering and Concurrent Tender Offer
Skadden, Arps, Slate, Meagher & Flom advised PayPal, while Davis Polk advised the joint book-running managers and representatives of the underwriters and the dealer manager in...
Bausch + Lomb’s $630 Million Initial Public Offering
Davis Polk advised Bausch Health Companies Inc. in connection with the separation of its eye health business into a new publicly traded company, Bausch + Lomb...
Qualcomm’s $1.5 Billion Notes Offering
Cravath represented Qualcomm, while Davis Polk advised the representatives of the several underwriters in the offering. Qualcomm Incorporated executed its offering of $500 million aggregate principal...
SiTime’s At-The-Market Offering
Cooley advised SiTime Corporation, while Davis Polk advised the sales agent, Stifel, Nicolaus & Company, in the offering. SiTime Corporation issued an SEC-registered at-the-market offering consisting of...
Deciphera Pharmaceuticals’ $172.5 Million Stock and Pre-Funded Warrants Offering
Davis Polk advised the joint book-running managers, J.P. Morgan Securities LLC and Jefferie, in the offering. Deciphera Pharmaceuticals, Inc. executed a $172.5 million SEC-registered common stock and...
Medtronic’s Acquisition of Left-Heart Access Business from Acutus
Davis Polk advised Acutus Medical on the deal. Acutus Medical, Inc. announced the sale of its left-heart access portfolio products to Medtronic, for an upfront payment of...
ArchiMed’s $1.2 Billion Acquisition of Natus Medical
Davis Polk advised Natus Medical Incorporated on the deal, while Latham & Watkins represented ArchiMed in the transaction. ArchiMed Group executed its approximately $1.2 billion acquisition of Natus...
Charles River Laboratories’ $295 Million Acquisition of Explora BioLabs Holdings
Davis Polk advised Charles River Laboratories International on the deal. Charles River Laboratories International, Inc. announced its $295 million acquisition of Explora BioLabs Holdings, Inc. Charles...
Monarch Alternative Capital’s $150 Million Investment in The Honest Kitchen
Davis Polk advised Monarch Alternative Capital on the deal. Monarch Alternative Capital LP announced its $150 million minority investment in The Honest Kitchen. Monarch will partner...
Denali Therapeutics’ $400 Million At-The-Market Offering
Davis Polk advised the sales agents in the transaction. The transaction consists in a new SEC-registered at-the-market offering program by Denali Therapeutics Inc. under which Denali...